Introduction {#s1}
============

Urological cancers, which consist of prostate cancer (PCa), bladder cancer (BC), and renal cell cancer (RCC) are common malignancies with increasing incidence and mortality worldwide (Torre et al., [@B36]). According to the most recent cancer statistics, urological cancers constitute more than 33% of all cancers in the United States in 2016 (Siegel et al., [@B32]). PCa, specifically, is the most common cancer in males accounting for 21% of new diagnoses with about 180, 890 new cases (Siegel et al., [@B32]). Aside from environmental factors, like tobacco exposure, genetic predisposition also involved in the occurrence and development of urological cancers (Mikhaylova et al., [@B22]; Solomon et al., [@B33]; Attard et al., [@B2]). Single nucleotide polymorphisms (SNPs) are the most common form of genetic variation in the human genome and widely implicated in cancer occurrence, development, and treatment response (Sachidanandam et al., [@B30]; Zheng et al., [@B41]; Rothman et al., [@B28]; Laurie et al., [@B19]).

micro RNAs (miRNAs) are a group of small non-coding RNAs with \~22 nucleotides in length that play key roles in vital biological processes such as cell differentiation, metabolism, intracellular signaling, immunity, and cell movement (Bartel, [@B3]). Over the past decade, accumulating evidence has demonstrated that some SNPs occurred in miRNAs can alter miRNA physiological function such as interaction with the translation of messenger RNA (mRNA) to regulate the expression level of target genes, and thus showed great potential for risk assessment, diagnosis and prognosis evaluation in different cancers (Ameres and Zamore, [@B1]). Hu et al. identified the early-stage NSCLC patients with an SNP, miR-30c-1 rs928508, had a better survival and the prognostic predictive value of miR-30c-1 rs928508 risk score was significantly increased (Hu et al., [@B17]).

Recently, SNPs in miRNAs (miR-SNPs) have been confirmed to be associated with urological cancer risks in different studies (Chirila et al., [@B4]; Filella and Foj, [@B9]). Nikolic et al. provided the evidence that miR-27a rs895819 was associated with the presence of distant metastasis among PCa patients (Nikolic et al., [@B24]). miR-196a2 C\>T (rs11614913), miR-146a G\>C (rs2910164), and miR-499 A\>G (rs3746444) have been widely studied to evaluate the correlation with the risk of urological cancers. However, the research results cannot reach consensus. For miR-196a2 C\>T (rs11614913), Mittal et al. found that there was no association between the individuals carrying the variant genotype of the miRNA and bladder cancer risk (Mittal et al., [@B23]). On the contrary, Deng et al. suggested mir-196a2 rs11614913 was associated with a significantly decreased risk of bladder cancer (Deng et al., [@B5]). Therefore, we performed a meta-analysis of the related publications to systematically evaluate the association between these miR-SNPs and cancer risk, which may with the potential to be used as clinical parameters for assessing the risk of occurrence, development, as well as for response to treatment of urological cancers (Ryan et al., [@B29]; Eeles et al., [@B7]; Shukla et al., [@B31]).

Materials and methods {#s2}
=====================

Literature search strategy
--------------------------

The databases including PubMed, Embase, Web of Science and CNKI were comprehensively searched to obtain literatures that reported the association between urological cancers and miRNA polymorphisms and that published in English or Chinese up to November 13, 2016. The search terms were as follows: "bladder cancer," "testis cancer," "prostate cancer," "kidney cancer," "microRNA," "miRNAs," "polymorphism," and "polymorphisms." In addition, to identify the additional relevant literatures, the references of searched studies were also examined carefully and the combined phrases were used.

Inclusion and exclusion criteria
--------------------------------

If the obtained studies fulfilled the following criteria, they were identified eligible: (1) case-control design; (2) research on the association between polymorphisms in microRNAs and risk of urological cancer; (3) sufficient published genotype frequencies data to estimate the odds ratio (OR) and 95% confidence interval (CI). The exclusion criteria included: (1) the genotype frequencies data was unavailable; (2) animal model research; (3) review articles, case reports, meta-analysis; (4) overlapping publications (the studies with more subjects or recently published were included).

Data extraction
---------------

There were two independent researchers (Ji and Luo) to extract the data from all included studies for analysis, including first author, year of publication, country, ethnicity (classified as either Asian or non-Asian), source of controls, number of different genotypes, Hardy-Weinberg equilibrium (HWE) for controls, genotyping method and cancer type. The third reviewer (Wang) joined the discussion if some discrepancies existed.

Quality assessment
------------------

The quality scoring criteria was modified from previous literatures and the score ranged from 0 point to 9 points (Table [1](#T1){ref-type="table"}; Niu et al., [@B26]). Two independent investigators (Wang and Ji) evaluated the quality of articles according to the modified criteria. A study with a score of ≥6 was defined as high quality, meantime one with a score \<6 was low quality.

###### 

**The criteria for quality assessment**.

  **Criteria**                                                                   **Score**
  ------------------------------------------------------------------------------ -----------
  **REPRESENTATIVENESS OF CASES**                                                
  Continuous collection and representative cases within clearly defined limits   2
  With potential selection bias                                                  1
  Not described                                                                  0
  **SOURCE OF CONTROLS**                                                         
  Population-based                                                               2
  Hospital-based                                                                 1
  Not described                                                                  0
  **HARDY-WEINBERG EQUILIBRIUM IN CONTROLS**                                     
  Hardy-Weinberg equilibrium                                                     2
  Hardy-Weinberg disequilibrium                                                  1
  **GENOTYPING EXAMINATION**                                                     
  Genotyping done under "blinded" condition                                      1
  Unblinded done or not mentioned                                                0
  **STATISTICAL METHODS**                                                        
  Appropriate statistics and adjustment for confounders                          2
  Appropriate statistics but without adjustment for confounders                  1
  Inappropriate statistics used                                                  0

Statistical analysis
--------------------

To assess the strength of the association between the three polymorphisms in miRNA and urological cancer risks, the odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were served as effect size. For the miR-196a2 C\>T (rs11614913) polymorphism, the allelic (T vs. C), heterozygous (CT vs. CC), homozygous (TT vs. CC), dominant (CT+TT vs. CC) and recessive (TT vs. CC+CT) genetic models were used to obtain pooled ORs. These models were also applied to assess the miR-146a G\>C (rs2910164), and miR-499 A\>G (rs3746444) polymorphisms. The subgroup analysis was performed according to cancer type, ethnicity, source of controls and HWE status of controls. The Cochran\'s Q statistic and *I*^2^ test were used to access the heterogeneity between different studies (Higgins, [@B14]). Heterogeneity was acceptable when the *P*-value was more than 0.10 and *I*^2^ was \<50%, and a fixed-effects model (the Mantel-Haenszel method) was used. In contrast, ORs were calculated by the random effects model (DerSimonian and Laird method; Mantel and Haenszel, [@B21]; Higgins et al., [@B15]). To evaluate the robustness of the results, we further performed the sensitivity analysis. Publication bias was conducted using Egger\'s linear regression and Begg\'s funnel plots (Hayashino et al., [@B13]). Statistical analysis of the data was calculated using the STATA version 12.0 (Stata Corp, College Station, TX, USA) with two-sided *P*-value. *P*-value was \< 0.05 was considered significant.

Results {#s3}
=======

Study characteristics
---------------------

In the beginning, a total of 589 relevant publications was identified after a systematic literature search using our search strategy (Figure [1](#F1){ref-type="fig"}). 571 of 589 publications were excluded in the step of duplicate removed, title and abstract screening, and article review. Then, 18 articles were remained to further access the eligibility by reviewing the full article. Four articles were excluded due to lacking HWE information. Eventually, 14 eligible articles (29 studies for polymorphisms analysis of individual miRNA) were selected for our present meta-analysis. Eleven studies focused on miR-196a2 C\>T (rs11614913) (Horikawa et al., [@B16]; Yang et al., [@B40]; George et al., [@B10]; Mittal et al., [@B23]; Du et al., [@B6]; Deng et al., [@B5]; Nikolic et al., [@B24]; Hashemi et al., [@B12]; Toraih et al., [@B34],[@B35]); 11 studies focused on miR-146a G\>C (rs2910164) (Horikawa et al., [@B16]; Yang et al., [@B40]; Xu et al., [@B39]; George et al., [@B10]; Mittal et al., [@B23]; Wang et al., [@B37]; Du et al., [@B6]; Nikolic et al., [@B25]; Deng et al., [@B5]; Huang et al., [@B18]; Hashemi et al., [@B12]) and seven studies focused on miR-499 A\>G (rs3746444) (George et al., [@B10]; Mittal et al., [@B23]; Du et al., [@B6]; Deng et al., [@B5]; Nikolic et al., [@B24]; Hashemi et al., [@B12]; Toraih et al., [@B34]). Five articles (George et al., [@B10]; Mittal et al., [@B23]; Du et al., [@B6]; Deng et al., [@B5]; Hashemi et al., [@B12]) investigated polymorphisms of these three miRNAs. miR-196a2 C\>T (rs11614913) and miR-146a G\>C (rs2910164) were simultaneously detected in four articles (Horikawa et al., [@B16]; Yang et al., [@B40]; Nikolic et al., [@B24]; Toraih et al., [@B34]). Table [2](#T2){ref-type="table"} presented the characteristics of the included studies. 10 studies focused on the association of miRNA polymorphisms and bladder cancer (Yang et al., [@B40]; Mittal et al., [@B23]; Wang et al., [@B37]; Deng et al., [@B5]; Toraih et al., [@B34]) or prostate cancer (Xu et al., [@B39]; Nikolic et al., [@B25], [@B24]; Hashemi et al., [@B12]), respectively. There were nine studies on renal cell cancer (Horikawa et al., [@B16]; Du et al., [@B6]; Huang et al., [@B18]; Toraih et al., [@B34],[@B35]). A large portion of studies were performed in Asian and the control was chosen from healthy population. As for the genotyping method, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used in 13 out of 29 studies. Some emerging tools, such as Taqman and SNPlex were applied to other studies. Within the genotype distribution in the controls, the value of HWE was either extracted in the articles directly or calculated using the data of controls. And only three studies (George et al., [@B10]; Mittal et al., [@B23]; Hashemi et al., [@B12]) deviated from HWE. The quality score of studies was also showed in Table [2](#T2){ref-type="table"}.

![**Flow diagram of the study selection process**.](fphys-08-00325-g0001){#F1}

###### 

**Main characteristics of included studies on microRNA polymorphisms and urological cancer risk**.

  **First author**                  **Year**   **Country**   **Ethnicity**   **Source of controls**   **Case**   **Control**   **Genotype distribution**   **Genotyping methods**   ***P* for HWE^a^**   **Cancer type**   **Quality score**                                                                  
  --------------------------------- ---------- ------------- --------------- ------------------------ ---------- ------------- --------------------------- ------------------------ -------------------- ----------------- ------------------- ----- ----------------------- --------- ---------------------- ---
  **miR-196a2 C\>T (rs11614913)**                                                                                                                                                                                                                                                                             
                                    **CC**     **CT**        **TT**          **CC**                   **CT**     **TT**                                                                                                                                                                                       
  Horikawa                          2008       America       Non-Asian       Population               276        277           105                         126                      45                   101               117                 59    SNPlex                  0.02      Renal cell carcinoma   8
  Yang                              2008       America       Non-Asian       Population               736        731           255                         348                      133                  257               117                 132   SNPlex                  0.33      Bladder cancer         8
  George                            2011       Indian        Asian           Population               159        230           55                          101                      3                    106               342                 10    PCR-RFLP                \< 0.01   Prostate cancer        7
  Mittal                            2011       Indian        Asian           Hospital                 212        250           76                          131                      5                    109               114                 14    PCR-RFLP                \< 0.01   Bladder cancer         7
  Du                                2014       China         Asian           Population               353        362           43                          189                      121                  74                127                 109   TaqMan                  0.97      Renal cell carcinoma   8
  Deng                              2015       China         Asian           Population               159        298           41                          66                       52                   56                179                 76    PCR-RFLP                0.04      Bladder cancer         7
  Nikolic                           2015       Serbia        Non-Asian       Population               355        312           150                         161                      40                   121               166                 41    PCR-RFLP                0.73      Prostate cancer        8
  Hashemi                           2016       Iran          Asian           Hospital                 169        182           64                          88                       17                   77                147                 12    T-ARMS-PCR              0.02      Prostate cancer        7
  Toraih a                          2016       Egypt         Non-Asian       Population               14         100           3                           10                       1                    55                93                  10    TaqMan                  0.221     Renal cell carcinoma   8
  Toraih a                          2016       Egypt         Non-Asian       Population               13         100           7                           3                        3                    55                35                  10    TaqMan                  0.221     Bladder cancer         8
  Toraih b                          2016       Egypt         Non-Asian       Population               65         150           23                          31                       11                   80                53                  17    TaqMan                  0.082     Renal cell carcinoma   6
  **miR-146a G\>C (rs2910164)**                                                                                                                                                                                                                                                                               
                                    **GG**     **GC**        **CC**          **GG**                   **GC**     **CC**                                                                                                                                                                                       
  Horikawa                          2008       America       Non-Asian       Population               261        235           144                         103                      14                   126               94                  15    SNPlex                  0.65      Renal cell carcinoma   8
  Yang                              2008       America       Non-Asian       Population               691        674           414                         242                      35                   385               258                 31    SNPlex                  0.14      Bladder cancer         7
  Xu                                2010       China         Asian           Population               215        280           68                          135                      48                   54                150                 76    PCR-RFLP                0.19      Prostate cancer        7
  George                            2011       Indian        Asian           Population               159        230           4                           79                       76                   7                 107                 116   PCR-RFLP                \< 0.01   Prostate cancer        7
  Mittal                            2011       Indian        Asian           Hospital                 212        250           127                         79                       6                    135               108                 7     PCR-RFLP                0.01      Bladder cancer         8
  Wang                              2012       China         Asian           Hospital                 1,017      1,179         369                         456                      192                  340               571                 268   Taqman                  0.34      Bladder cancer         6
  Du                                2014       China         Asian           Population               353        362           68                          167                      118                  57                190                 115   Taqman                  0.14      Renal cell carcinoma   8
  Nikolic                           2014       Serbia        Non-Asian       Population               286        199           184                         90                       12                   129               63                  7     Taqman                  0.84      Prostate cancer        7
  Deng                              2015       China         Asian           Population               159        298           26                          73                       60                   32                154                 112   PCR-RFLP                0.05      Bladder cancer         7
  Huang                             2015       China         Asian           Hospital                 421        432           80                          236                      105                  69                234                 129   ABI sequencing system   0.03      Renal cell carcinoma   7
  Hashemi                           2016       Iran          Asian           Hospital                 169        182           25                          131                      13                   24                147                 11    T-ARMS-PCR              \< 0.01   Prostate cancer        6
  **miR-499 A\>G (rs3746444)**                                                                                                                                                                                                                                                                                
                                    **AA**     **AG**        **GG**          **AA**                   **AG**     **GG**                                                                                                                                                                                       
  George                            2011       Indian        Asian           Population               159        230           48                          98                       13                   104               92                  34    PCR-RFLP                0.07      Prostate cancer        8
  Mittal                            2011       Indian        Asian           Hospital                 212        250           95                          92                       25                   121               94                  35    PCR-RFLP                0.02      Bladder cancer         8
  Du                                2014       China         Asian           Population               354        362           251                         94                       9                    255               96                  11    Taqman                  0.59      Renal cell carcinoma   8
  Deng                              2015       China         Asian           Population               159        298           107                         45                       7                    216               68                  14    PCR-RFLP                0.01      Bladder cancer         7
  Nikolic                           2015       Serbia        Non-Asian       Population               355        307           190                         147                      18                   180               110                 17    PCR-RFLP                0.97      Prostate cancer        8
  Hashemi                           2016       Iran          Asian           Hospital                 169        182           62                          82                       25                   85                64                  33    PCR-RFLP                \< 0.01   Prostate cancer        6
  Toraih b                          2016       Egypt         Non-Asian       Population               65         150           6                           17                       42                   57                66                  27    TaqMan                  0.307     Renal cell carcinoma   6

*Population, Population controls; Hospital, Hospital controls; PCR-RFLP, polymerase chain reaction--restriction fragment length polymorphism; T-ARMS-PCR, tetra-primer amplification refractory mutation system polymerase chain reaction; HWE, Hardy-Weinberg equilibrium*.

Quantitative data synthesis
---------------------------

There were 11 eligible studies with 2,511 cases and 2,992 controls that focused on the association of miR-196a2 rs11614913 C\>T and urological cancer risks. Overall, no significant association was revealed in the pooled results under any genetic model statistically. Table [3](#T3){ref-type="table"} presented the detailed results of the meta-analysis. The heterogeneity was significantly reduced by stratified analysis. Through stratified analyses by cancer type, heterozygote CT had an effect of increasing the risk of renal cell carcinoma compared with homozygote CC (OR = 1.72, 95%CI = 1.05--2.80, *P* = 0.03 *I*^2^ = 66%). However, miR-196a2 rs11614913 C\>T showed no significant correlation with risks in prostate cancer and bladder cancer. In ethnicity subgroup analysis, significantly increased cancer risks were observed in Asian populations for allele genetic model (OR = 1.17, 95%CI = 1.04--1.32, *P* \< 0.01, *I*^2^ = 0%). For subgroup analysis based on source of controls and HWE status of controls, no significant association was found. Sensitivity analysis showed that none of the studies leaded to change the global ORs, indicating the robustness and stable of the results in this meta-analysis. Begg\'s funnel plot and Egger\'s test showed that no obvious publication bias existed in the eligible literatures (T vs. C: *P* = 0.08; TC vs. CC: *P* = 0.33; TT vs. CC: *P* = 0.68; TC+ TT vs. CC: *P* = 0.15; TT vs. CC+ TC: *P* = 0.78).

###### 

**Summary ORs and 95% CI of microRNA polymorphisms and urological cancer risk**.

  **Variables**          **N**   **T vs. C**               **CT vs. CC**   **TT vs. CC**   **CT+TT vs. CC**          **TT vs. CC+CT**                                                                                                                                                          
  ---------------------- ------- ------------------------- --------------- --------------- ------------------------- ------------------ ----------- ------------------------- ------------ ----------- ------------------------- ------------ ----------- ------------------------- ---------- ------------
  mir-196a2                      OR (95%CI)                P               *I*^2^(%)       OR (95%CI)                P                  *I*^2^(%)   OR (95%CI)                P            *I*^2^(%)   OR (95%CI)                P            *I*^2^(%)   OR (95%CI)                P          *I*^2^ (%)
  Total                  11      1.07 \[0.99, 1.16\]       0.08            43              1.21 \[0.96, 1.54\]       0.11               67          1.06 \[0.89, 1.26\]       0.5          45          1.21 \[0.98, 1.50\]       0.08         64          1.03 \[0.89, 1.20\]       0.67       36
  **CANCER TYPE**                                                                                                                                                                                                                                                                              
  Prostate cancer        3       1.04 \[0.89, 1.22\]       0.6             47              1.18 \[0.80, 1.74\]       0.41               66          0.93 \[0.62, 1.38\]       0.7          35          1.16 \[0.80, 1.69\]       0.43         65          0.92 \[0.63, 1.33\]       0.65       41
  Bladder cancer         4       1.03 \[0.92, 1.16\]       0.6             0               0.94 \[0.62, 1.44\]       0.78               71          0.98 \[0.76, 1.25\]       0.85         0           1.03 \[0.87, 1.22\]       0.75         49          1.08 \[0.70, 1.69\]       0.72       56
  Renal cell carcinoma   4       1.27 \[0.92, 1.76\]       0.15            73              **1.72 \[1.05, 2.80\]**   **0.03**           **66**      1.42 \[0.73, 2.76\]       0.3          70          1.69 \[0.99, 2.89\]       0.06         74          1.04 \[0.82, 1.32\]       0.74       39
  **ETHNICITY**                                                                                                                                                                                                                                                                                
  Asian                  5       **1.17 \[1.04, 1.32\]**   **\<0.01**      **0**           1.25 \[0.84, 1.85\]       0.27               76          1.13 \[0.69, 1.86\]       0.63         56          1.28 \[0.93, 1.78\]       0.13         68          1.17 \[0.94, 1.47\]       0.17       48
  Non-Asian              6       1.06 \[0.87, 1.29\]       0.55            56              1.14 \[0.85, 1.53\]       0.38               54          0.96 \[0.78, 1.20\]       0.74         30          1.12 \[0.85, 1.48\]       0.42         57          0.94 \[0.77, 1.14\]       0.54       11
  **DESIGN**                                                                                                                                                                                                                                                                                   
  Hospital               2       1.14 \[0.93, 1.41\]       0.2             0               1.32 \[0.99, 1.76\]       0.06               0           0.98 \[0.30, 3.18\]       0.98         68          1.30 \[0.98, 1.73\]       0.07         0           0.84 \[0.22, 3.18\]       0.8        77
  Population             9       1.10 \[0.95, 1.26\]       0.19            53              1.20 \[0.90, 1.61\]       0.22               72          1.06 \[0.89, 1.27\]       0.52         47          1.20 \[0.92, 1.57\]       0.17         70          1.04 \[0.89, 1.21\]       0.62       30
  **HWE**                                                                                                                                                                                                                                                                                      
  HWE-Yes                6       1.17 \[0.96, 1.44\]       0.12            62              1.34 \[0.93, 1.95\]       0.12               69          1.32 \[0.89, 1.95\]       0.16         54          1.36 \[0.95, 1.96\]       0.09         71          1.07 \[0.89, 1.28\]       0.46       0
  HWE-No                 5       1.05 \[0.93, 1.19\]       0.46            5               1.12 \[0.79, 1.59\]       0.53               72          0.85 \[0.63, 1.15\]       0.29         11          1.12 \[0.84, 1.49\]       0.46         61          0.89 \[0.54, 1.46\]       0.64       63
                                 C vs. G                   GC vs. GG       CC vs. GG       CC+GC vs. GG              CC vs. GC+GG                                                                                                                                                              
  mir-146a                       OR (95%CI)                P               *I*^2^(%)       OR (95%CI)                P                  *I*^2^(%)   OR (95%CI)                P            *I*^2^(%)   OR (95%CI)                P            *I*^2^(%)   OR (95%CI)                P          *I*^2^(%)
  Total                  11      **0.87 \[0.81,0.93\]**    **\<0.01**      **0**           **0.81 \[0.73,0. 90\]**   **\<0.01**         **0**       **0.73 \[0.63,0.85\]**    **\<0.01**   **0**       **0.80 \[0.72,0.88\]**    **\<0.01**   **0**       **0.87 \[0.77,0.98\]**    **0.02**   **0**
  **CANCER TYPE**                                                                                                                                                                                                                                                                              
  Prostate cancer        4       0.89 \[0.77,1.03\]        0.11            30              0.87 \[0.68, 1.12\]       0.29               0           0.71 \[0.49, 1.05\]       0.08         32          0.85 \[0.66, 1.08\]       0.18         1           0.83 \[0.64,1.07\]        0.15       14
  Bladder cancer         4       **0.84 \[0.77, 0.92\]**   **\<0.01**      **0**           **0.78 \[0.68, 0.89\]**   **\<0.01**         **0**       **0.72 \[0.59, 0.87\]**   **\<0.01**   **0**       **0.77 \[0.68, 0.88\]**   **\<0.01**   **5**       0.87 \[0.73, 1.03\]       0.1        0
  Renal cell carcinoma   3       0.91 \[0.80, 1.03\]       0.13            0               0.86 \[0.69, 1.07\]       0.17               0           0.78 \[0.59, 1.03\]       0.08         0           0.85 \[0.68, 1.04\]       0.12         0           0.91 \[0.74, 1.12\]       0.35       8
  **ETHNICITY**                                                                                                                                                                                                                                                                                
  Asian                  8       **0.85 \[0.78, 0.91\]**   **\<0.01**      **0**           **0.76 \[0.66, 0.86\]**   **\<0.01**         **0**       **0.69 \[0.59, 0.82\]**   **\<0.01**   **0**       **0.74 \[0.65, 0.83\]**   **\<0.01**   **0**       **0.85 \[0.75, 0.97\]**   **0.01**   **0**
  Non-Asian              3       0.95 \[0.83, 1.09\]       0.5             0               0.91 \[0.77, 1.09\]       0.31               0           1.01 \[0.69, 1.48\]       0.97         0           0.93 \[0.78, 1.09\]       0.36         0           1.04 \[0.71, 1.52\]       0.83       0
  **DESIGN**                                                                                                                                                                                                                                                                                   
  Hospital               4       **0.83 \[0.76, 0.91\]**   **\<0.01**      **0**           **0.77 \[0.66, 0.90\]**   **\<0.01**         **0**       **0.69 \[0.57, 0.84\]**   **\<0.01**   **0**       **0.75 \[0.65, 0.86\]**   **\<0.01**   **0**       **0.81 \[0.68, 0.95\]**   **0.01**   **0**
  Population             7       0.91 \[0.83, 1.00\]       0.05            0               0.85 \[0.73, 0.98\]       0.02               0           0.79 \[0.63, 0.99\]       0.05         0           0.85 \[0.74, 0.98\]       0.02         0           0.94 \[0.79, 1.11\]       0.45       0
  **HWE**                                                                                                                                                                                                                                                                                      
  HWE-Yes                9       **0.86 \[0.80, 0.93\]**   **\<0.01**      **16**          **0.80 \[0.72, 0.90\]**   **\<0.01**         **0**       **0.72 \[0.61, 0.85\]**   **\<0.01**   **8**       **0.79 \[0.71, 0.89\]**   **\<0.01**   **14**      **0.87 \[0.76, 1.00\]**   **0.06**   **11**
  HWE-No                 2       0.89 \[0.78, 1.02\]       0.09            0               0.84 \[0.66, 1.07\]       0.16               0           0.79 \[0.56, 1.12\]       0.19         0           0.82 \[0.65, 1.04\]       0.1          0           0.86 \[0.68, 1.08\]       0.18       0
                                 G vs. A                   AG vs. AA       GG vs. AA       GG+AG vs. AA              GG vs. AG+AA                                                                                                                                                              
  mir-499                        OR(95%CI)                 P               *I*^2^(%)       OR (95%CI)                P                  *I*^2^(%)   OR(95%CI)                 P            *I*^2^(%)   OR(95%CI)                 P            *I*^2^(%)   OR(95%CI)                 P          *I*^2^(%)
  Total                  7       1.33 \[0.98, 1.81\]       0.06            85              **1.37 \[1.18, 1.60\]**   **\<0.01**         **49**      1.33 \[0.71, 2.48\]       0.38         79          **1.43 \[1.09, 1.88\]**   **\<0.01**   **67**      1.10 \[0.55, 2.23\]       0.78       87
  **CANCER TYPE**                                                                                                                                                                                                                                                                              
  Prostate cancer        3       1.16 \[0.98, 1.36\]       0.08            0               **1.68 \[1.17, 2.41\]**   **\<0.01**         **58**      0.96 \[0.65, 1.42\]       0.84         0           **1.45 \[1.17, 1.80\]**   **\<0.01**   **26**      0.72 \[0.50, 1.03\]       0.07       0
  Bladder cancer         2       1.09 \[0.87, 1.35\]       0.46            0               1.28 \[0.96, 1.72\]       0.09               0           0.94 \[0.57, 1.53\]       0.79         0           1.21 \[0.92, 1.59\]       0.18         0           0.85 \[0.53, 1.36\]       0.5        0
  Renal cell carcinoma   2       2.22\[0.42,11.65\]        0.35            97              1.37 \[0.59, 3.20\]       0.46               65          3.48 \[0.21, 58.88\]      0.39         95          2.31 \[0.38, 13.94\]      0.36         93          2.69 \[0.28, 25.73\]      0.39       94
  **ETHNICITY**                                                                                                                                                                                                                                                                                
  Asian                  5       1.09 \[0.95, 1.25\]       0.2             0               **1.43 \[1.07, 1.92\]**   **0.02**           **61**      0.93 \[0.67, 1.27\]       0.63         0           **1.27 \[1.07, 1.51\]**   **\<0.01**   **42**      0.74 \[0.55, 1.01\]       0.05       0
  Non-Asian              2       2.40\[0.54,10.75\]        0.25            97              1.35 \[1.00, 1.84\]       0.05               34          3.77 \[0.27, 53.30\]      0.33         95          2.57 \[0.54, 12.31\]      0.24         91          2.76 \[0.32, 24.12\]      0.36       95
  **DESIGN**                                                                                                                                                                                                                                                                                   
  Hospital               2       1.08 \[0.88, 1.33\]       0.44            0               **1.44 \[1.07, 1.94\]**   **0.02**           **18**      0.97 \[0.64, 1.48\]       0.88         0           1.30 \[0.98, 1.71\]       0.07         0           0.80 \[0.54, 1.19\]       0.28       0
  Population             5       1.47 \[0.94, 2.30\]       0.09            90              **1.44 \[1.05, 1.97\]**   **0.02**           **61**      1.56 \[0.58, 4.14\]       0.38         86          **1.54 \[1.04, 2.27\]**   **0.03**     **77**      1.26 \[0.43, 3.66\]       0.67       90
  **HWE**                                                                                                                                                                                                                                                                                      
  HWE-Yes                4       1.57 \[0.90, 2.74\]       0.12            92              1.49 \[0.99, 2.25\]       0.06               71          1.74 \[0.51, 5.89\]       0.38         89          **1.67 \[1.00, 2.77\]**   **0.05**     **83**      1.35 \[0.37, 4.97\]       0.65       92
  HWE-No                 3       1.11 \[0.93, 1.32\]       0.26            0               **1.41 \[1.10, 1.80\]**   **\<0.01**         **0**       0.97 \[0.66, 1.43\]       0.9          0           **1.29 \[1.02, 1.63\]**   **0.03**     **0**       0.82 \[0.57, 1.18\]       0.29       0

*Population, Population controls; Hospital, Hospital controls; N, number of studies. The bold values mean the results were statistically significant*.

A total of 11 eligible studies, consisting of 3,943 cases and 4,321 controls focused on miR-146a rs2910164 G\>C. The overall OR with its 95% CI revealed a significantly reduced risk of urological cancers in all the five genetic models (C vs. G: OR = 0.87, 95%CI = 0.81--0.93, *P* \< 0.01, *I*^2^ = 0%; GC vs. GG: OR = 0.81, 95%CI = 0.73--0.90, *P* \< 0.01, *I*^2^ = 0%; CC vs. GG: OR = 0.73, 95%CI = 0.63--0.85, *P* \< 0.01, *I*^2^ = 0%; CC+GC vs. GG: OR = 0.80, 95%CI = 0.72--0.88, *P* \< 0.01, *I*^2^ = 0%; CC vs. GC+GG: OR = 0.87, 95%CI = 0.77--0.98, *P* = 0.02, *I*^2^ = 0%, Figure [2](#F2){ref-type="fig"}; Table [3](#T3){ref-type="table"}). In the tumor type stratified analysis, significant reduced cancer risk was found in four genetic models of bladder cancer (C vs. G: OR = 0.84, 95%CI = 0.77--0.92, *P* \< 0.01, *I*^2^ = 0%; GC vs. GG: OR = 0.78, 95%CI = 0.68--0.89, *P* \< 0.01, *I*^2^ = 0%; CC vs. GG: OR = 0.72, 95%CI = 0.59--0.87, *P* \< 0.01, *I*^2^ = 0%; CC+GC vs. GG: OR = 0.77, 95%CI = 0.68--0.88, *P* \< 0.01, *I*^2^ = 5%, Figure [3](#F3){ref-type="fig"}; Table [3](#T3){ref-type="table"}). For prostate cancer and renal cell carcinoma, no diversity was detected. In subgroup analysis by ethnicity, we also observed significantly reduced cancer risks in Asian populations for all genetic models (C vs. G: OR = 0.85, 95%CI = 0.78--0.91, *P* \< 0.01, *I*^2^ = 0%; GC vs. GG: OR = 0.76, 95%CI = 0.66--0.86, *P* \< 0.01, *I*^2^ = 0%; CC vs. GG: OR = 0.69, 95%CI = 0.59--0.82, *P* \< 0.01, *I*^2^ = 0%; CC+GC vs. GG: OR = 0.74, 95%CI = 0.65--0.83, *P* \< 0.01, *I*^2^ = 0%; CC vs. GC+GG: OR = 0.85, 95%CI = 0.75--0.97, *P* = 0.01, *I*^2^ = 0%, Figure [4](#F4){ref-type="fig"}; Table [3](#T3){ref-type="table"}). Furthermore, reduced cancer risk was also observed by the analysis restricted to HWE studies in all genetic models. And these results were consistent with analysis of the hospital control group (Figure [5](#F5){ref-type="fig"}). Sensitivity analysis was conducted, and no change of the result was detected (Figure [6](#F6){ref-type="fig"}). Meanwhile, no publication bias was observed with Egger\'s test (C vs. G: *P* = 0.08; GC vs. GG: *P* = 0.59; CC vs. GG: *P* = 0.07; CC+GC vs. GG: *P* = 0.54; CC vs. GC+GG: *P* = 0.18; Figure [7](#F7){ref-type="fig"}).

![**OR and 95% CIs for the associations between microRNA-146a rs2910164 G\>C polymorphism and urological cancer risk in dominant genetic model for overall populations**.](fphys-08-00325-g0002){#F2}

![**OR and 95% CIs for the associations between microRNA-146a rs2910164 G\>C polymorphism and urological cancer risk in dominant genetic model stratified by cancer type**.](fphys-08-00325-g0003){#F3}

![**OR and 95% CIs for the associations between microRNA-146a rs2910164 G\>C polymorphism and urological cancer risk in dominant genetic model stratified by ethnicity**.](fphys-08-00325-g0004){#F4}

![**OR and 95% CIs for the associations between microRNA-146a rs2910164 G\>C polymorphism and urological cancer risk in dominant genetic model stratified by source of control**.](fphys-08-00325-g0005){#F5}

![**Sensitivity analysis through the deletion of each study to reflect the individual influence on the calculated ORs in dominant genetic model of microRNA-146a rs2910164 G\>C polymorphism**.](fphys-08-00325-g0006){#F6}

![**Funnel plot analysis to detect publication bias for dominant genetic model of microRNA-146a rs2910164 G\>C polymorphism. The weight of studies is presented by the size of circles**.](fphys-08-00325-g0007){#F7}

For miR-499 rs3746444 A\>G polymorphism, seven studies that focused on the association of miR-499 rs3746444 A\> G polymorphism and urological cancer risk involving 1,473 cases and 1,779 controls were pooled into the meta-analysis. Significant association was found in two genetic models (AG vs. AA: OR = 1.37, 95%CI = 1.18--1.60, *P* \< 0.01, *I*^2^ = 49%; GG+AG vs. AA: OR = 1.43, 95%CI = 1.09--1.88, *P* \< 0.01, *I*^2^ = 67%; Table [3](#T3){ref-type="table"}), as well as in Asian populations (AG vs. AA: OR = 1.43, 95%CI = 1.07--1.92, *P* = 0.02, *I*^2^ = 61%; GG+AG vs. AA: OR = 1.27, 95%CI = 1.07--1.51, *P* \< 0.01, *I*^2^ = 42%; Table [3](#T3){ref-type="table"}). Significant association with increased urological cancer risk was also observed in AG vs. AA genetic models (OR = 1.44, 95%CI = 1.07--1.94, *P* = 0.02, *I*^2^ = 18%; Table [3](#T3){ref-type="table"}) in hospital-based controls and two genetic models (AG vs. AA: OR = 1.44, 95%CI = 1.05--1.97, *P* = 0.02, *I*^2^ = 61%; GG+AG vs. AA: OR = 1.54, 95%CI = 1.04--2.27, *P* = 0.03, *I*^2^ = 77%; Table [3](#T3){ref-type="table"}) in population-based control groups. Meanwhile, miR-499 rs3746444 A\>G showed significant correlation with risks in prostate cancer (AG vs. AA: OR = 1.68, 95%CI = 1.17--2.41, *P* \< 0.01, *I*^2^ = 58%; GG+AG vs. AA: OR = 1.45, 95%CI = 1.17--1.80, *P* \< 0.01, *I*^2^ = 26%). The pooled ORs did not display any change with sensitivity analysis. Publication bias was not conducted because of the small number of studies (\<10) focused on miR-499 rs3746444 A\>G polymorphism.

Discussion {#s4}
==========

Since SNPs in miRNA genes could potentially influence the miRNA biogenesis and alter target selection (Georges et al., [@B11]), increasing attention has been paid to evaluate the correlation between the polymorphisms in microRNAs and cancer risk (Ryan et al., [@B29]). Because miRNAs must correctly recognize their target sites, a SNP in microRNA may affect the process of the post-transcriptional regulation, which may cause the dysregulation of their target genes and subsequently relate to disease susceptibility. In a meta-analysis conducted by Feng et al. ([@B8]) identified that mir-149 rs2292832 may contribute to increased susceptibility of breast cancer. Significantly increased risk between miR-146a rs2910164 and head and neck cancer (HNC) risk was observed in Caucasian population (Niu et al., [@B27]). While the finding of a meta-analysis revealed that no significant association was observed between miR-149 rs2292832 and overall cancer risk, the miR-146a rs2910164 is a protective factor for bladder cancer, prostate cancer in Asians (Ma et al., [@B20]).

In the present meta-analysis, we discussed three SNPs in miRNAs (rs11614913, rs2910164, and rs3746444) which were considered to have certain correlation to cancer risk by pooled results from 29 eligible case-control studies including 7,927 cases and 9,092 controls. The results demonstrated that miR-146a rs2910164 G\>C was a significantly reduced urological cancer risk, especially for bladder cancer, which is in agreement with the work conducted by Ma et al. ([@B20]). It has been shown that miR-146a inhibited bladder cancer progression by targeting PTTG1, which may be the target of bladder cancer therapy (Xiang et al., [@B38]). Our results further confirmed that miR-146a rs2910164 G\>C can reduce the risk of bladder cancer. miR-499 rs3746444 A\>G polymorphism might play an important role in the development of urological cancer and might influence the risk of prostate cancer. As for miR-196a2 rs11614913 C\>T, no significant association was found. However, in the subgroup analysis by cancer type, T mutation increased the risk of developing renal cell carcinoma in the CT vs. CC genetic model. Interestingly, subgroup analyses by ethnicity showed a significant association with urological cancer risk in all three polymorphisms in Asian populations. Our meta-analysis also confirmed the results of previous studies that different distribution of genotype may be a crucial risk for urological cancer susceptibility in different ethnicity (Hashemi et al., [@B12]). This discrepancy might be caused due to different living environment, diets, climate and lifestyles.

To our knowledge, it was the first quantitative study focused on the association between microRNA polymorphisms and urological cancer risk specially to date. The strengths our study are listed as follows: first, most of the genotype distributions in controls were consistent with HWE. Second, the relationship was analyzed by using five kinds of genetic models, and the results were statistically significant. Third, the methodological issues for meta-analysis, such as Egger\'s test, Begg\'s funnel plots and subgroup analysis were performed to ensure the stability of the results.

However, we also pay attention to the limitations in our meta-analysis. Firstly, the small sample size of studies included was still inadequate, so that the statistical power was reduced. Secondly, the effects of combination genetic and environmental factors could not be taken into account because accurate individual information was not available. Thirdly, there might exist publication bias because of the inclusion of published articles only. Finally, the diversity of genotyping methods could partly bring about the change of analyzed results.

In conclusion, the data of our meta-analysis indicate that the miR-146a rs2910164 C allele is a protective gene mutation for urological cancer, especially for bladder cancer in Asian. miR-499 rs3746444 polymorphisms may contribute to increased susceptibility of urological cancer. However, miR-196a2 rs11614913 only serve as a risk factor for renal cell carcinoma in particular in Asian populations. Further multi-centric investigation still need to confirm the relationship of these polymorphisms in microRNAs and urological cancer susceptibility.
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